Skip to content

US · MTVA

MetaVia Inc.

Sector
Healthcare · Biotechnology
Headquarters
Cambridge, MA 02138

Price · as of 2026-09-04

$1.75

Market cap 3.28M

Price history

Weekly OHLC price history for MTVA, USD per share
WeekOpenHighLowCloseVolume
Nov 4, 2024 – Nov 8, 2024$27.50$32.89$26.51$30.800
Nov 11, 2024 – Nov 15, 2024$32.45$32.45$23.98$24.420
Nov 18, 2024 – Nov 22, 2024$25.41$27.50$24.75$26.070
Nov 25, 2024 – Nov 29, 2024$27.50$29.15$25.30$28.050
Dec 2, 2024 – Dec 6, 2024$25.63$29.15$22.44$25.410
Dec 9, 2024 – Dec 13, 2024$24.64$27.50$23.98$24.090
Dec 16, 2024 – Dec 20, 2024$25.30$27.50$17.05$17.600
Dec 23, 2024 – Dec 27, 2024$18.26$21.23$16.61$19.360
Dec 30, 2024 – Jan 3, 2025$20.68$24.09$19.36$23.540
Jan 6, 2025 – Jan 10, 2025$24.42$30.25$22.00$22.660
Jan 13, 2025 – Jan 17, 2025$23.65$23.87$20.46$21.450
Jan 20, 2025 – Jan 24, 2025$21.01$22.00$19.91$21.120
Jan 27, 2025 – Jan 31, 2025$21.45$23.54$19.25$19.910
Feb 3, 2025 – Feb 7, 2025$19.14$20.57$18.70$19.030
Feb 10, 2025 – Feb 14, 2025$19.58$21.34$17.82$18.370
Feb 17, 2025 – Feb 21, 2025$18.26$19.47$16.61$17.600
Feb 24, 2025 – Feb 28, 2025$18.04$18.37$14.19$16.060
Mar 3, 2025 – Mar 7, 2025$16.06$18.48$15.18$17.050
Mar 10, 2025 – Mar 14, 2025$17.05$18.26$15.51$16.280
Mar 17, 2025 – Mar 21, 2025$17.16$18.04$16.28$17.050
Mar 24, 2025 – Mar 28, 2025$16.83$17.93$16.61$17.380
Mar 31, 2025 – Apr 4, 2025$16.72$18.15$15.62$16.060
Apr 7, 2025 – Apr 11, 2025$15.62$16.83$13.86$15.950
Apr 14, 2025 – Apr 17, 2025$15.95$23.10$7.12$8.130
Apr 21, 2025 – Apr 25, 2025$8.02$9.46$7.37$9.050
Apr 28, 2025 – May 2, 2025$9.13$9.13$8.08$8.570
May 5, 2025 – May 9, 2025$8.35$8.80$7.26$8.020
May 12, 2025 – May 16, 2025$7.93$8.06$7.15$7.530
May 19, 2025 – May 23, 2025$7.48$9.63$7.35$8.690
May 26, 2025 – May 30, 2025$8.58$8.86$6.96$7.150
Jun 2, 2025 – Jun 6, 2025$7.40$7.84$7.15$7.610
Jun 9, 2025 – Jun 13, 2025$7.72$8.80$7.61$8.050
Jun 16, 2025 – Jun 20, 2025$8.14$8.32$7.44$7.440
Jun 23, 2025 – Jun 27, 2025$7.41$7.80$6.93$6.930
Jun 30, 2025 – Jul 3, 2025$7.16$7.43$6.88$7.130
Jul 7, 2025 – Jul 11, 2025$7.13$8.14$6.62$7.900
Jul 14, 2025 – Jul 18, 2025$7.87$7.97$7.21$7.410
Jul 21, 2025 – Jul 25, 2025$7.70$8.20$7.32$7.760
Jul 28, 2025 – Aug 1, 2025$7.70$7.78$6.60$6.700
Aug 4, 2025 – Aug 8, 2025$7.08$7.27$6.11$6.930
Aug 11, 2025 – Aug 15, 2025$7.16$7.30$6.71$7.040
Aug 18, 2025 – Aug 22, 2025$7.04$7.26$6.67$7.150
Aug 25, 2025 – Aug 29, 2025$7.10$7.24$6.80$6.980
Sep 1, 2025 – Sep 5, 2025$6.82$7.70$6.82$7.590
Sep 8, 2025 – Sep 12, 2025$7.81$7.81$7.27$7.660
Sep 15, 2025 – Sep 19, 2025$7.56$19.03$7.50$11.440
Sep 22, 2025 – Sep 26, 2025$10.67$12.10$10.45$10.670
Sep 29, 2025 – Oct 3, 2025$10.67$11.44$9.91$11.330
Oct 6, 2025 – Oct 10, 2025$11.55$12.87$10.56$10.760
Oct 13, 2025 – Oct 17, 2025$11.22$12.21$9.90$10.700
Oct 20, 2025 – Oct 24, 2025$10.84$11.44$10.37$10.780
Oct 27, 2025 – Oct 31, 2025$10.78$11.11$10.45$10.920
Nov 3, 2025 – Nov 7, 2025$10.89$14.85$8.28$9.990
Nov 10, 2025 – Nov 14, 2025$9.24$9.24$6.82$7.690
Nov 17, 2025 – Nov 21, 2025$7.92$9.30$7.28$7.640
Nov 24, 2025 – Nov 28, 2025$7.59$8.79$7.59$8.560
Dec 1, 2025 – Dec 5, 2025$8.53$8.58$6.05$8.180
Dec 8, 2025 – Dec 12, 2025$10.27$13.42$8.01$9.310
Dec 15, 2025 – Dec 19, 2025$9.37$9.37$7.81$8.620
Dec 22, 2025 – Dec 26, 2025$8.62$10.00$8.40$9.190
Dec 29, 2025 – Jan 2, 2026$9.19$9.56$8.01$9.560
Jan 5, 2026 – Jan 9, 2026$9.61$9.61$8.01$8.150
Jan 12, 2026 – Jan 16, 2026$8.17$8.31$2.95$3.110
Jan 19, 2026 – Jan 23, 2026$3.10$3.14$2.74$2.830
Jan 26, 2026 – Jan 30, 2026$2.90$2.90$2.32$2.430
Feb 2, 2026 – Feb 6, 2026$2.58$2.87$1.66$1.820
Feb 9, 2026 – Feb 13, 2026$1.84$1.96$1.54$1.640
Feb 16, 2026 – Feb 20, 2026$1.64$1.72$1.43$1.550
Feb 23, 2026 – Feb 27, 2026$1.58$1.73$1.50$1.510
Mar 2, 2026 – Mar 6, 2026$1.51$1.68$1.50$1.550
Mar 9, 2026 – Mar 13, 2026$1.56$1.68$1.34$1.610
Mar 16, 2026 – Mar 20, 2026$1.62$1.64$1.36$1.410
Mar 23, 2026 – Mar 27, 2026$1.49$1.55$1.21$1.220
Mar 30, 2026 – Apr 2, 2026$1.22$1.29$1.17$1.260
Apr 6, 2026 – Apr 10, 2026$1.27$1.46$1.17$1.410
Apr 13, 2026 – Apr 17, 2026$1.50$1.60$1.36$1.400
Apr 20, 2026 – Apr 24, 2026$1.40$1.67$1.38$1.560
Apr 27, 2026 – May 1, 2026$1.58$1.67$1.41$1.440
May 4, 2026 – May 8, 2026$1.43$1.54$1.00$1.090
May 11, 2026 – May 15, 2026$1.19$1.24$0.97$1.110
May 18, 2026 – May 22, 2026$1.10$4.31$1.08$3.850
May 25, 2026 – May 29, 2026$3.35$3.80$2.73$2.840
Jun 1, 2026 – Jun 5, 2026$2.73$2.96$2.32$2.570
Jun 8, 2026 – Jun 12, 2026$2.21$2.41$1.70$1.740
Jun 15, 2026 – Jun 18, 2026$1.70$1.92$1.57$1.600
Jun 22, 2026 – Jun 26, 2026$1.60$1.66$1.41$1.430
Jun 29, 2026 – Jul 2, 2026$1.43$1.56$1.38$1.480
Jul 6, 2026 – Jul 10, 2026$1.41$1.80$1.41$1.780
Jul 13, 2026 – Jul 17, 2026$1.76$2.61$1.68$1.710
Jul 20, 2026 – Jul 24, 2026$1.76$1.76$1.42$1.480
Jul 27, 2026 – Jul 31, 2026$1.49$1.52$1.38$1.420
Aug 3, 2026 – Aug 7, 2026$1.48$1.56$1.43$1.490
Aug 10, 2026 – Aug 14, 2026$1.44$1.52$1.42$1.490
Aug 17, 2026 – Aug 21, 2026$1.50$1.54$1.43$1.460
Aug 24, 2026 – Aug 28, 2026$1.44$1.80$1.44$1.700
Aug 31, 2026 – Sep 4, 2026$1.70$1.93$1.65$1.750

Valuation

MetricValueUpside
IC Value
P/E-0.22
P/B0.53
P/S
EV/EBITDA0.56
PEG
P/TBV0.53

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

Annual price and model valuations for MTVA, USD per share
YearPriceAIICGraham-DoddGraham Formula
2011
2012
2013
2014
2015
2016$605,220.00
2017$508,860.00
2018$84,480.00
2019$43,507.20
2020$11,695.20
2021$1,995.84
2022$63.62
2023$58.96
2024$17.05
2025$1.61

Historic valuation ratios

Pick a category, then toggle metrics to compare.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MetaVia Inc.

        Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

        CEO
        Hyung Heon Kim
        Employees
        8
        Beta
        0.97

        Peer comparison

        Same-industry comparables, ranked by market cap.

        Scroll horizontally for additional metrics. Ticker column stays fixed.

        Peer comparison for MTVA: basic info, valuation models, ratios, profitability, leverage, growth, cash flow, dividends, enterprise value, and Altman Z-score.
        Basic InfoIC ValuationCore ValuationProfitabilityLeverage & LiquidityGrowthCash FlowDividendsEnterprise ValueRisk
        TickerCompany NamePriceMarket CapValueUpsideP/EP/BP/SEV/EBITDAPEGP/TBVGross MarginOperating MarginNet MarginROEROICROADebt/EquityInterest CoverageCurrent RatioQuick RatioNet Debt/EBITDAEPS GrowthSales GrowthFCF GrowthFCF YieldOp Cash Flow RatioCash ROICDividend YieldDividend PayoutShareholder YieldEV/EBITEV/FCFEV/SalesAltman Z-Score
        MTVAMetaVia Inc.$1.493.28M-0.220.530.560.530.00%0.00%0.00%-195.61%216.13%-30.39%0.041.931.820.78-81.23%-36.47%-552.28%-2.78247.58%0.00%0.00%0.00%0.530.46-3.55
        CLGNCollPlant Biotechnologies…$0.344.39M$35.20+10,288%-0.621.173.01-0.381.1926.32%-484.31%-484.56%-117.56%-301.63%-77.90%0.47-765.532.532.230.29-35.17%360.39%-35.19%-132.33%-3.53-248.15%0.00%0.00%0.00%-0.35-0.431.70-18.14
        ENLVEnlivex Therapeutics Ltd.$2.0835.01M0.040.02-2.880.040.00%0.00%0.00%126.17%-1.19%104.94%0.00-1153.85193.240.680.09-3590.41%-20.04%-22.06%-1.15-1.09%0.00%0.00%0.00%-2.82-4.031.61
        LSTALisata Therapeutics, Inc.$1.069.65M$15.41+1,354%-2.632.94257.03-1.592.9414.12%-10711.18%-9756.47%-74.67%1304.83%-62.89%0.005.765.420.92-20.42%-83.00%-17.46%-36.56%-5.191211.30%0.00%0.00%0.00%-1.52-1.74163.17-38.60
        NCNANuCana plc$1.478.93M-0.180.220.89-0.130.240.00%0.00%0.00%-193.87%-26313.49%-131.60%0.035.605.581.15137.00%-60.54%-146.37%-1.56-10421.77%0.00%0.00%325.15%0.912.39-12.61
        PASGPassage Bio, Inc.$4.4014.14M-0.521.26-0.031.260.00%0.00%0.00%-113.78%-1339.47%-55.28%1.282.072.010.50-33.07%-34.34%-133.30%-1.37-978.08%0.00%0.00%43.13%-0.03-0.04-17.33
        XCURExicure, Inc.$1.358.57M$4.64+245%-5.356.74-4.47-6.210.00%0.00%0.00%-92.47%-3231.53%-34.00%0.04-10117.001.190.980.70-50.31%-100.00%194.02%-32.35%-2.20-3083.24%0.00%0.00%0.00%-2.26-2.67-21.11

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.75) − 1 = — (IC, example).